ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Oric Pharmaceuticals Inc.

Roth MKM analyst reiterated a Buy rating on Oric Pharmaceuticals today and set a price target of $15.00. Currently, the analyst consensus on Oric P...

Roth MKM Reaffirms Their Buy Rating on Oric Pharmaceuticals (ORIC)

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Oric Pharmaceuticals, with a price target of $15.00. Accord...

Oppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)

In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Oric Pharmaceuticals, with a price target of $20.00. Accordi...

Wedbush Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)

Oric Pharmaceuticals ( ($ORIC) ) has issued an update. On December 6, 2025, Oric Pharmaceuticals presented an update on its enozertinib (ORIC-114) ...

Oric Pharmaceuticals Highlights Promising Enozertinib Trial Results

Oric Pharmaceuticals Inc (ORIC) has disclosed a new risk, in the Employment / Personnel category. Oric Pharmaceuticals Inc.’s strategic pipeline pr...

Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications

Wedbush analyst David Nierengarten maintained a Buy rating on Oric Pharmaceuticals today and set a price target of $20.00. Nierengarten covers the ...

The latest announcement is out from Oric Pharmaceuticals ( ($ORIC) ). Oric Pharmaceuticals announced an update on their ORIC-944 clinical trials, h...

Current Quarter	$-0.33	Next Quarter	$-0.34
Current Year	$-1.56	Next Year	$-1.54
QoQ Growth	-3.0%	YoY Growth	+1.3%
3Y EPS CAGR	N/A	Target Price	$19.92
Consensus	Buy	Upside	+85.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ORIC	$10.75	-2.28%	1.37M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ORIC	$10.75	-2.3%	1.37M
3
4
5
6

ORIC

ORIC

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Oric Pharmaceuticals Inc. Data in Excel

Get Oric Pharmaceuticals Inc. Data in Excel